Biotech gene-editing specialist Intellia Therapeutics (NASDAQ: NTLA) is set to have a big year, at least if we go by the most recent business update management gave us. In a press release Thursday morning, Intellia Therapeutics outlined its strategic priorities for the new year, and these anticipated events have investors excited. This explains why shares of the biotech are rising sharply on Thursday, up by 14.7% as of 12:26 p.m. EST.
In 2021, Intellia Therapeutics expects to submit a couple of Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA), according to the press release. The company will submit an IND (or IND-equivalent) for NTLA-5001 for the treatment of acute myeloid leukemia in mid-2021. The biotech is also planning to submit an IND for NTLA-2002, a potential treatment for hereditary angioedema, in the second half of the year. These INDs, if approved, would allow the company to advance clinical trials for both of these candidates.